Nevro Corp (NVRO): Michael Enxing , VP of Sales & Marketing of Nevro Corp sold 1,500 shares on May 4, 2016. The Insider selling transaction was reported by the company on May 6, 2016 to the Securities and Exchange Commission. The shares were sold at $65.29 per share for a total value of $97,595.63 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Apr 5, 2016, Michael Enxing (VP of Sales & Marketing) sold 8,767 shares at $61.56 per share price.On Apr 5, 2016, Rami Elghandour (President) sold 7,000 shares at $61.06 per share price.Also, On Jan 13, 2016, Andre Walker (Senior VP,Research&Development) sold 7,987 shares at $71.00 per share price.On Jan 13, 2016, Doug Alleavitch (VP, Quality and Operations) sold 1,000 shares at $70.00 per share price.
Shares of Nevro Corp (NVRO) ended Wednesday, May 4, 2016 session in red amid volatile trading. The shares closed down -1.8 points or -2.75% at $63.74 with 4,00,196 shares getting traded. Post opening the session at $64.85, the shares hit an intraday low of $63.65 and an intraday high of $66.28 and the price vacillated in this range throughout the day. The company has a market cap of $1,796 M and the number of outstanding shares has been calculated to be 2,81,81,547 shares. The 52-week high of Nevro Corp is $72.51 and the 52-week low is $36.51.
Nevro Corp. is a medical device company. The Company manufactures and markets active implantable medical devices for the treatment of neurological disorders initially focusing on the treatment of chronic pain. The Company developed and commercialized a neuromodulation platform for the treatment of chronic pain. The Company’s Senza system is the only spinal cord stimulation (SCS) system that delivers its HF10 therapy. The Company’s Senza system creates electrical impulses from two hertz to 10 kilohertz including its HF10 therapy which allows for pain relief without paresthesia. HF10 therapy delivers waveforms at 10 kilohertz pulse rate with a statistically driven and clinically verified programming algorithm. Senza consists of leads a trial stimulator an implantable pulse generator (IPG) surgical tools a clinician laptop programmer a patient remote control and a mobile charger.